- Conditions
- Unilateral Cataract Extraction, Congenital Cataract
- Interventions
- OMS302, Phenylephrine HCl
- Drug
- Lead sponsor
- Omeros Corporation
- Industry
- Eligibility
- 1 Day to 47 Months
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Cataract Extraction
- Interventions
- OMS302, OMS302-PE, Vehicle
- Drug
- Lead sponsor
- Omeros Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- Redding, California • Bloomington, Minnesota • Kansas City, Missouri + 1 more
- Conditions
- Pain, Inflammation
- Interventions
- Nepafenac PPDS, Placebo PPDS
- Combination Product
- Lead sponsor
- Mati Therapeutics Inc.
- Industry
- Eligibility
- 22 Years to 99 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 3
- States / cities
- Edgewood, Kentucky • Garden City, New York • Mt. Pleasant, South Carolina
- Conditions
- Patients Having Undergone Unilateral Cataract Extraction and Implantation of a Monofocal
- Interventions
- Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA
- Drug
- Lead sponsor
- Eyegate Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Inflammation
- Interventions
- VVN461 Ophthalmic Solution 1.0%, VVN461 Ophthalmic Solution 0.5%, Vehicle
- Drug
- Lead sponsor
- VivaVision Biotech, Inc
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 10
- States / cities
- Inglewood, California • Petaluma, California • Rancho Cordova, California + 7 more
- Conditions
- Cataract
- Interventions
- OMS302 Solution, OMS302 Mydriatic Solution, OMS302 Anti-inflammatory Solution, Balanced Salt Solution (BSS) Solution
- Drug
- Lead sponsor
- Omeros Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 24
- States / cities
- Chandler, Arizona • Glendale, Arizona • Little Rock, Arkansas + 21 more
- Conditions
- Cataract Unilateral, Aphakia
- Interventions
- IOL
- Device
- Lead sponsor
- Estelle Poineau
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 369 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Cape Coral, Florida